{
  "metadata": {
    "case_id": 45,
    "model": "Claude-4.5-Sonnet",
    "timestamp": "2025-11-29T16:19:47.910710",
    "total_alignments": 2,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/45_NCT04324073.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Claude-4.5-Sonnet/45_Claude-4.5-Sonnet.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 4,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.86,
          0.18
        ],
        [
          0.32,
          0.95
        ],
        [
          0.88,
          0.03
        ],
        [
          0.3,
          0.93
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "SARILUMAB -- Severe COVID population (WHO Clinical Progression Scale =5 at baseline)",
            "type": "EXPERIMENTAL",
            "description": "Sarilumab (an IV dose of 400 mg of sarilumab in a 1 hour-infusion at Day 1). Administration of Sarilumab fixed dose on day 3 was recommended and left to the treating physician",
            "interventionNames": [
              "Drug: Sarilumab"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "label": "Standard of care -- Severe COVID population (WHO Clinical Progression Scale =5 at baseline)",
            "type": "NO_INTERVENTION",
            "description": "Usual care was provided at the discretion of the clinicians"
          },
          "pred_item": {
            "label": "Usual care group",
            "type": "NO_INTERVENTION",
            "description": "Patients received usual care alone (antibiotic agents, antiviral agents, corticosteroids, vasopressor support, anticoagulants) provided at the discretion of the clinicians",
            "interventionNames": [
              "Other: Usual care"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 0,
          "score": 0.88,
          "status": "matched",
          "ref_item": {
            "label": "SARILUMAB -- Critical COVID population (WHO Clinical Progression Scale >5 at baseline)",
            "type": "EXPERIMENTAL",
            "description": "Sarilumab (an IV dose of 400 mg of sarilumab in a 1 hour-infusion at Day 1). Administration of Sarilumab fixed dose on day 3 was recommended and left to the treating physician",
            "interventionNames": [
              "Drug: Sarilumab"
            ]
          },
          "pred_item": {
            "label": "Sarilumab group",
            "type": "EXPERIMENTAL",
            "description": "Patients received usual care plus sarilumab 400 mg intravenously on day 1, with an optional additional 400 mg dose on day 3 if oxygen requirement had not decreased by more than 50%",
            "interventionNames": [
              "Drug: Sarilumab",
              "Other: Usual care"
            ]
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "Standard of care -- Critical COVID population (WHO Clinical Progression Scale >5)",
            "type": "NO_INTERVENTION",
            "description": "Usual care was provided at the discretion of the clinicians"
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.96,
          0.2
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Sarilumab",
            "description": "(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1",
            "armGroupLabels": [
              "SARILUMAB -- Critical COVID population (WHO Clinical Progression Scale >5 at baseline)",
              "SARILUMAB -- Severe COVID population (WHO Clinical Progression Scale =5 at baseline)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Sarilumab",
            "description": "400 mg administered intravenously on day 1, with possible additional 400 mg dose on day 3 based on clinical response (if oxygen requirement had not decreased by more than 50%)",
            "armGroupLabels": [
              "Sarilumab group"
            ]
          }
        }
      ]
    }
  ]
}